Clinical Trial Update: Iron Isomaltoside 1000 (Monofer®) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a high-dose regimen of Iron Isomaltoside 1000 (Monofer) in inflammatory bowel disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Bowel Disease

Drugs mentioned

• Monofer (Ferric derisomaltose)

Snippet

Sponsor: Pharmacosmos A/S | Conditions: Inflammatory Bowel Disease | Phase 3 | Status: COMPLETED